1,035 Shares in Stryker Co. (NYSE:SYK) Bought by Kelleher Financial Advisors

Kelleher Financial Advisors bought a new position in Stryker Co. (NYSE:SYK) in the second quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 1,035 shares of the medical technology company’s stock, valued at approximately $316,000.

A number of other institutional investors have also modified their holdings of the stock. Bank Julius Baer & Co. Ltd Zurich grew its position in shares of Stryker by 95,685.2% during the 2nd quarter. Bank Julius Baer & Co. Ltd Zurich now owns 4,942,516 shares of the medical technology company’s stock valued at $1,507,912,000 after acquiring an additional 4,937,356 shares during the period. Norges Bank acquired a new stake in shares of Stryker during the 4th quarter valued at about $776,333,000. Moneta Group Investment Advisors LLC grew its position in shares of Stryker by 109,726.8% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 3,139,948 shares of the medical technology company’s stock valued at $767,686,000 after acquiring an additional 3,137,089 shares during the period. Ontario Teachers Pension Plan Board grew its position in shares of Stryker by 87,902.2% during the 1st quarter. Ontario Teachers Pension Plan Board now owns 2,077,732 shares of the medical technology company’s stock valued at $555,482,000 after acquiring an additional 2,075,371 shares during the period. Finally, FMR LLC grew its position in shares of Stryker by 50.5% during the 1st quarter. FMR LLC now owns 6,012,525 shares of the medical technology company’s stock valued at $1,716,396,000 after acquiring an additional 2,017,006 shares during the period. Hedge funds and other institutional investors own 76.24% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. Morgan Stanley lifted their price objective on Stryker from $295.00 to $300.00 and gave the stock an “equal weight” rating in a report on Monday, August 7th. Barclays lifted their price objective on Stryker from $321.00 to $335.00 and gave the stock an “overweight” rating in a report on Monday, August 7th. Citigroup lowered their price objective on Stryker from $342.00 to $330.00 and set a “buy” rating on the stock in a report on Monday, October 2nd. Truist Financial lifted their price objective on Stryker from $270.00 to $300.00 and gave the stock a “hold” rating in a report on Monday, November 6th. Finally, Bank of America upgraded Stryker from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $310.00 to $315.00 in a report on Tuesday, September 5th. Five equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $311.30.

Stryker Price Performance

SYK stock opened at $292.03 on Friday. The firm has a 50 day moving average of $275.10 and a 200-day moving average of $282.63. Stryker Co. has a 12-month low of $220.74 and a 12-month high of $306.93. The company has a current ratio of 1.48, a quick ratio of 0.83 and a debt-to-equity ratio of 0.58. The company has a market cap of $110.94 billion, a price-to-earnings ratio of 43.26, a PEG ratio of 2.71 and a beta of 0.94.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, November 2nd. The medical technology company reported $2.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.43 by $0.03. Stryker had a net margin of 13.00% and a return on equity of 22.62%. The company had revenue of $4.90 billion during the quarter, compared to the consensus estimate of $4.87 billion. During the same period last year, the firm earned $2.12 EPS. The company’s revenue for the quarter was up 9.4% on a year-over-year basis. As a group, equities analysts expect that Stryker Co. will post 10.41 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Srikant M. Datar sold 500 shares of the business’s stock in a transaction on Thursday, November 16th. The shares were sold at an average price of $291.92, for a total transaction of $145,960.00. Following the completion of the sale, the director now directly owns 4,316 shares of the company’s stock, valued at approximately $1,259,926.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other Stryker news, Director Srikant M. Datar sold 500 shares of the business’s stock in a transaction on Thursday, November 16th. The shares were sold at an average price of $291.92, for a total value of $145,960.00. Following the transaction, the director now owns 4,316 shares in the company, valued at approximately $1,259,926.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Srikant M. Datar sold 750 shares of the business’s stock in a transaction on Tuesday, November 14th. The stock was sold at an average price of $287.57, for a total transaction of $215,677.50. Following the completion of the transaction, the director now owns 5,316 shares in the company, valued at approximately $1,528,722.12. The disclosure for this sale can be found here. In the last three months, insiders sold 6,250 shares of company stock valued at $1,806,638. Company insiders own 5.90% of the company’s stock.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies.